Table 1.

Nuclear S100A6 expression and association with clinicopathologic variables

VariableAll cases, n = 60, n (%)Nuclear S100A6 strong/moderate, n = 47, n (%)Nuclear S100A6 weak/negative, n = 13, n (%)Significance
Gender
    Male34 (57)24 (51)10 (77)NS *
    Female26 (43)23 (49)3 (23)
Age at surgery (y)
    <6018 (30)13 (28)5 (38)NS *
    >6042 (70)34 (72)8 (62)
Tumor size (mm)
    <2021 (35)18 (38)3 (23)NS *
    >2039 (65)29 (62)10 (77)
Tumor grade
    Poorly differentiated23 (38)19 (40)4 (31)NS
    Moderate differentiated31 (52)25 (53)6 (46)
    Well differentiated6 (10)3 (7)3 (23)
Nodal metastases
    Present48 (80)37 (79)11 (85)NS *
    Not present12 (20)10 (21)2 (15)
Involved resection margin
    Yes37 (62)28 (60)9 (69)NS *
    No23 (38)19 (40)4 (31)
Vascular invasion
    Present29 (48)24 (51)5 (38)NS *
    Not present17 (28)12 (26)5 (38)
    Not recorded 14 (24)11 (23)3 (24)
Neural invasion
    Present37 (62)29 (62)8 (62)NS *
    Not present7 (12)5 (11)2 (23)
    Not recorded 16 (26)13 (17)3 (15)
p53 expression
    p53 overexpression20 (33)15 (32)5 (38)NS *
    p53 low/negative40 (67)32 (68)8 (62)
Smad4 expression
    Smad4 positive28 (47)24 (51)4 (31)NS *
    Smad4 negative25 (42)17 (36)8 (62)
    Not recorded 7 (11)6 (13)1 (7)
  • Abbreviation: NS, not significant.

  • * Fisher's two-sided exact test (P < 0.05).

  • χ2 test (P < 0.05).

  • Data incomplete.